Press-release for stocks related to als

Prices are updated after-hours

tags : Als crawled time : 14:00

save search

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
Published: 2024-01-09 (Crawled : 14:00) - biospace.com/
NRSN | News | $1.33 -2.21% -2.26% 130K

| 72.2% | O: 6.36% H: 3.57% C: -1.67%
primec disease als positive trial

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Published: 2023-11-09 (Crawled : 14:00) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| 151.85% | O: -1.24% H: 5.01% C: -0.62%
als therapeutics

DarkPulse, Inc. JV Company, Neural Logistics, Seeks FDA Designation For ALS Patients
Published: 2023-08-01 (Crawled : 14:00) - globenewswire.com
DPLS | $0.0009 81.82% 6.4M

Information

| -62.96% | O: -3.7% H: 7.69% C: 0.0%
fda als designation

Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M

| -92.13% | O: -1.65% H: 0.0% C: -5.38%
amx0035 chmp als treatment pharmaceuticals application negative

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
Published: 2023-04-10 (Crawled : 14:00) - biospace.com/
DNLI | $15.55 -3.48% -3.6% 940K

Health Technology

| -33.65% | O: -1.07% H: 0.79% C: 0.21%
dnl343 als meeting therapeutics

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
COYA | News | $8.28 3.24% 3.14% 120K

| 100.5% | O: 1.25% H: 0.0% C: -4.94%
als association therapeutics study

Spod Lithium Corp. Engages ALS GoldSpot Discoveries Ltd. for Mag/VLF Airborne Survey on Nipigon & Niemi Lithium Project
Published: 2023-01-25 (Crawled : 14:00) - globenewswire.com
LTUM | $0.0351 33.16% 410K

Mining, Quarrying, and Oil and ...

| -70.3% | O: -6.31% H: 14.74% C: 10.94%
als lithium

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
Published: 2022-11-15 (Crawled : 14:00) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -13.65% | O: 17.46% H: 6.49% C: -8.11%
fda clearance als study phase 2b

BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Published: 2022-11-10 (Crawled : 14:00) - biospace.com/
BCLI A | $0.5339 1.7% 1.67% 190K

Health Technology

| -81.66% | O: -58.48% H: 56.67% C: 39.17%
nurown treatment fda als application license therapeutics

Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M

| -93.41% | O: -0.95% H: 5.8% C: 3.24%
als trial

Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS
Published: 2022-07-29 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M

| -92.59% | O: 0.87% H: 2.37% C: 1.73%
treatment canada als

Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
SEEL | $0.2971 -9.17% -10.1% 600K

Health Technology

| -63.19% | O: 2.67% H: 2.13% C: -6.11%
sls-005 label australia als therapeutics update sclerosis study platform

Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
Published: 2022-07-05 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M

| -89.98% | O: 16.23% H: 2.39% C: -13.83%
amx0035 treatment fda als review

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALSManaged Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022
Published: 2022-06-16 (Crawled : 14:00) - biospace.com/
CYTK | $66.76 1.82% 1.78% 810K

Health Technology

| 59.5% | O: -2.48% H: 0.0% C: 0.0%
trials extension als program

Neuvivo Begins Manufacturing of NP001 for Treatment of ALS
Published: 2022-05-11 (Crawled : 14:00) - biospace.com/
TMO | News | $577.39 0.49% 0.0% 2M

Health Technology

| 7.45% | O: -0.88% H: 0.0% C: 0.0%
np001 treatment als

NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC
Published: 2022-04-06 (Crawled : 14:00) - biospace.com/
NRSN | News | $1.33 -2.21% -2.26% 130K

| -63.78% | O: 1.46% H: 1.28% C: -10.5%
drug patent primec canada als granted therapeutics grant

Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis
Published: 2022-03-22 (Crawled : 14:00) - biospace.com/
ZNTL | $11.76 -6.44% -6.89% 850K

Health Technology

| -74.32% | O: 1.12% H: 4.75% C: 2.51%
phase 1 als potential

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001
Published: 2022-03-18 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| -14.48% | O: 1.03% H: 0.0% C: 0.0%
lnk0100 partnership als commercialization 100

New Analysis from Global Industry Analysts Reveals Steady Growth for Organic Foods and Beverages, with the Market to Reach $411.9 Billion Worldwide by 2026
Published: 2022-03-16 (Crawled : 14:00) - prnewswire.com
GIS 4 | $71.61 1.12% 0.0% 4.4M

Consumer Non-Durables

| 11.92% | O: 0.08% H: 0.08% C: -1.07%
als foods food growth

Global Road Marking Materials Market to Reach $7.5 Billion by 2026
Published: 2022-03-16 (Crawled : 14:00) - prnewswire.com
MMM | $92.02 -1.05% 0.0% 3.8M

Producer Manufacturing

| -35.56% | O: 0.31% H: 1.04% C: 0.52%
als